The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer

International Journal of Radiation Oncology Biology Physics

Volumn 35, Issue 4, 1996, Pages 669-677

  Fowble, Barbara ^a   Fein, Douglas A ^a   Hanlon, Alexandra L ^a   Eisenberg, Burton L ^a   Hoffman, John P ^a   Sigurdson, Elin R ^a   Daly, Mary B ^a   Goldstein, Lori J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Adjuvant tamoxifen; Breast cancer; Conservative surgery and radiation

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; EXCISION; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030199596     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(96)00185-X     Document Type: Article

References (31)

1. 1. American Joint Committee on Cancer. In: Manual for staging of cancer. Philadelphia, PA: J. P. Lippincott Co; 1983:127-134.
2. 2. Armitage, P. Statistical methods of medical research. New York: John Wiley & Sons, Inc; 1973:135-136.
3. 3. Breast Cancer Trials Committee. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet ii: 171-175; 1987.
4. 4. CRC Adjuvant Breast Trial Working Party. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br. J. Cancer 57:604-607; 1988.
5. 5. Cummings, F. J.; Gray, R.; Tormey, D. C.; Davis, T. E.; Volk, H.; Harris, J.; Falkson, G.; Bennett, J. M. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. J. Clin. Oncol. 11:29-35; 1993.
6. 6. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85; 1992.
7. 7. Fisher, B.; Anderson, S. Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP Trials. World Journal of Surgery 18:63-69; 1994.
8. 8. Fisher, B.; Costantino, J.; Redmond, C.; Poisson, R.; Bowman, D.; Couture, J.; Dimitrov, N. V.; Wolmark, N.; Wickerham, D. L.; Fisher, E. R.; Margolese, R.; Robidoux, A.; Shibata, H.; Terz, J.; Paterson, A. H. G.; Feldman, M. I.; Farrar, W.; Evans, J.; Lickley, H. L.; Ketner, M.; et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320:479-484; 1989.
9. 9. Fisher, B.; Costantino, J.; Wickerham, L.; Redmond, N.; Wolmark, R.; Margolese, D.; Bowman, D.; Dimitrov, N.; Robidoux, A.; Glass, A. Adjuvant therapy for node-negative breast cancer: an update of the NSABP findings (Abstract). Proc. Am. Soc. Clin. Oncol. 12:69; 1993.
10. 10. Fisher, B.; Redmond, C.; Fisher, E. R.; Caplan, R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project (Protocol B-06). J. Clin. Oncol. 6:1076-1087; 1988.
11. 11. Furr, B. J. A.; Jordan, V. C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 25:127-205; 1984.
12. 12. Haffty, B. G.; Wilmarth, L.; Wilson, L.; Fischer, D.; Beinfield, M.; McKhann, C. Adjuvant systemic chemotherapy and hormonal therapy affect on local recurrence in the conservatively treated breast cancer patient. Cancer 73:2543-2548; 1994.
13. 13. Jaiyesimi, I. A.; Buzdar, A. U.; Decker, D. A.; Hortobagyi, G. N. Use of tamoxifen for breast cancer: 28 years later. J. Clin. Oncol. 13:513-529; 1995.
14. 14. Kaplan, E. L.; Meier, P. Non-parametric estimation from incomplete observation. J. Am. Stat. Assoc. 53:457-481; 1958.
15. 15. Leborgne, F.; Leborgne, J. H.; Ortega, B.; Doldan, R.; Zubizarreta, E. Breast conservation treatment of early stage breast cancer: Patterns of failure. Int. J. Radiat. Oncol. Biol. Phys. 31:765-775; 1995.
16. 16. Ludwig Breast Cancer Study Group. Randomized trial of chemo-endocrine therapy and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet i: 1256-1260; 1984.
17. 17. Mantel, M. Evaluation of survival data and two new rank order statistics arising in its considerations. Cancer Chemother. Rep. 50:163-170; 1966.
18. 18. McCormick, B.; Hakes, T.; Yahalom, J.; Kinne, D.; Norton, L. Breast conserving surgery and radiation: The delay of primary radiation after adjuvant chemotherapy does not influence local control. Proc. Am. Soc. Clin. Oncol. 11:55; 1992.
19. 19. Mehta, C. R.; Patel, H. R. A network of algorithm for performing Fisher's exact test in R × C contingency tables. J. Am. Stat. Assoc. 78:427-434; 1983.
20. 20. Nolvadex Adjuvant Trial Organization. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: analysis at eight years. Br. J. Cancer 57:608-611; 1988.
21. 21. Osborne, C. K.; Boldt, D. H.; Clark, G. M.; Trent, J. M. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G 1 phase. Cancer Res. 43:3583-3585; 1983.
22. 22. Parry, B. R. Radiation recall induced by tamoxifen. Lancet 340:49; 1992.
23. 23. Pritchard, K. I.; Meakin, J. W.; Boyd, N. F.; DeBoer, G.; Paterson, A. H. G.; Ambus, U.; Dembo, A. J.; Sutherland, D. J. A.; Wilkinson, R. H.; Bassett, A. A.; Evans, W. K.; Beale, F, A.; Clark, R. M.; Keane, T. J. Adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer: An update. In: Salmon, S. E., ed. Adjuvant therapy of cancer. V. Orlando, FL: Grune & Stratton; 1987:391-400.
24. 24. Ribeiro, G.; Swindell, R. The Christie Hospital adjuvant tamoxifen trial-status at 10 years. Br. J. Cancer 57:601-603; 1988.
25. 25. Rose, C.; Thorpe, S. M.; Andersen, K. W.; Pedersen, B. V.; Mouridsen, H. T.; Blitchert-Toft, M.; Rasmussen, B. B. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet i:16-19; 1985.
26. 26. Rutqvist, L. E.; Cedermark, B.; Glas, U.; Johansson, H.; Nordenskjöld, B.; Skoog, L.; Somell, A.; Theve, T.; Friberg, S.; Askergren, J. The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res. Treat. 10:255-266; 1987.
27. 27. Rutqvist, L. E.; Cedermark, B.; Glas, U.; Johansson, H.; Rotstein, S.; Skoog, L.; Somell, A.; Theve, T.; Wilking, N.; Askergren, J.; Hjalmar, M.-L. Randomized trial of adjuvant tamoxifen combined with post-operative radiotherapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer 66:89-96; 1990.
28. 28. Rutqvist, L. E.; Cedermark, B.; Glas, U.; Johansson, H.; Rotstein, S.; Skoog, L.; Somell, A.; Theve, T.; Wilking, N.; Askergren, J.; Hjalmar, M.-L.; Ringborg, U. Randomized trial of adjuvant tamoxifen in node negative postmenopausal breast cancer. Acta Oncol. 31:265-270; 1992.
29. 29. Sinclair, W. K. Cyclic x-ray responses in the mammalian cells in vitro. Radiat. Res. 33:620-643; 1968.
30. 30. Taylor, M. E.; Perez, C. A.; Halverson, K. J.; Kuske, R. R.; Philpott, G. W.; Garcia, D. M.; Mortimer, J. E.; Myerson, R. J.; Radford, P.; Rush, C. Factors influencing cosmetic results after conservation therapy for breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 31:753-764; 1995.
31. 31. Wazer, D. E.; DiPetrillo, T.; Schmidt-Ullrich, R.; Weld, L.; Smith, T. J.; Marchant, D. J.; Robert, N. J. Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J. Clin. Oncol. 10:356-363; 1992.